Puzo Michael J Sells 270 Shares of CVS Health Corp (NYSE:CVS)

Puzo Michael J lowered its holdings in shares of CVS Health Corp (NYSE:CVS) by 0.4% during the 1st quarter, Holdings Channel reports. The firm owned 64,733 shares of the pharmacy operator’s stock after selling 270 shares during the quarter. CVS Health accounts for about 1.4% of Puzo Michael J’s investment portfolio, making the stock its 28th largest holding. Puzo Michael J’s holdings in CVS Health were worth $3,490,000 as of its most recent filing with the SEC.

Other hedge funds have also added to or reduced their stakes in the company. Brookmont Capital Management lifted its position in shares of CVS Health by 3.0% in the 4th quarter. Brookmont Capital Management now owns 5,184 shares of the pharmacy operator’s stock worth $340,000 after purchasing an additional 152 shares during the period. Clarus Wealth Advisors lifted its position in shares of CVS Health by 6.9% in the 4th quarter. Clarus Wealth Advisors now owns 2,456 shares of the pharmacy operator’s stock worth $161,000 after purchasing an additional 158 shares during the period. First City Capital Management Inc. lifted its position in shares of CVS Health by 0.9% in the 4th quarter. First City Capital Management Inc. now owns 21,433 shares of the pharmacy operator’s stock worth $1,404,000 after purchasing an additional 181 shares during the period. Boston Financial Mangement LLC lifted its position in shares of CVS Health by 0.4% in the 4th quarter. Boston Financial Mangement LLC now owns 42,340 shares of the pharmacy operator’s stock worth $2,774,000 after purchasing an additional 185 shares during the period. Finally, Capital Investment Advisory Services LLC lifted its position in shares of CVS Health by 3.8% in the 1st quarter. Capital Investment Advisory Services LLC now owns 5,128 shares of the pharmacy operator’s stock worth $277,000 after purchasing an additional 189 shares during the period. 77.48% of the stock is currently owned by institutional investors.

Shares of CVS Health stock opened at $54.59 on Friday. The company has a debt-to-equity ratio of 1.45, a current ratio of 0.95 and a quick ratio of 0.64. The stock has a market capitalization of $69.71 billion, a price-to-earnings ratio of 7.71, a PEG ratio of 1.08 and a beta of 0.89. CVS Health Corp has a 52-week low of $51.72 and a 52-week high of $82.15.

CVS Health (NYSE:CVS) last issued its earnings results on Wednesday, May 1st. The pharmacy operator reported $1.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.50 by $0.12. The business had revenue of $61.65 billion during the quarter, compared to analysts’ expectations of $60.39 billion. CVS Health had a negative net margin of 0.08% and a positive return on equity of 16.80%. The business’s revenue for the quarter was up 34.8% compared to the same quarter last year. During the same period in the previous year, the company earned $1.48 earnings per share. As a group, research analysts predict that CVS Health Corp will post 6.85 EPS for the current year.

CVS has been the subject of a number of recent research reports. Citigroup set a $74.00 price target on shares of CVS Health and gave the company a “buy” rating in a research report on Thursday, May 2nd. Argus lowered their price target on shares of CVS Health from $100.00 to $80.00 and set a “positive” rating for the company in a research report on Monday, February 25th. Sanford C. Bernstein initiated coverage on shares of CVS Health in a research report on Tuesday, March 12th. They set an “outperform” rating and a $76.00 price target for the company. Credit Suisse Group cut shares of CVS Health from an “outperform” rating to a “neutral” rating and lowered their price target for the company from $73.00 to $61.00 in a research report on Monday, April 29th. Finally, Wells Fargo & Co cut shares of CVS Health from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $104.00 to $68.00 in a research report on Wednesday, February 20th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the stock. CVS Health has an average rating of “Buy” and a consensus price target of $76.48.

COPYRIGHT VIOLATION WARNING: “Puzo Michael J Sells 270 Shares of CVS Health Corp (NYSE:CVS)” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://www.dispatchtribunal.com/2019/06/14/puzo-michael-j-sells-270-shares-of-cvs-health-corp-nysecvs.html.

CVS Health Profile

CVS Health Corporation provides health services and plans in the United States. Its Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, Medicare Part D, clinical, disease management, and medical spend management services.

Read More: How does the Beige Book influence monetary policy?

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corp (NYSE:CVS).

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.